What is Cepheid?
Headquartered in Sunnyvale, California, Cepheid specializes in the development, manufacturing, and marketing of advanced molecular systems and diagnostic tests. The company addresses a critical market need by automating complex, manual laboratory procedures, thereby enabling institutions of varying sizes to conduct high-precision genetic testing for organisms and genetic-based diseases. Since its founding in 1996, Cepheid has effectively bridged the gap between laboratory-grade complexity and point-of-care accessibility, establishing itself as a cornerstone of modern healthcare technology. Its core competencies lie in the integration of microfluidics and real-time PCR technology, which have become industry standards for rapid, accurate disease detection.
How much funding has Cepheid raised?
Cepheid has raised a total of $33M across 4 funding rounds:
Angel/Seed
$2.5M
Series A
$3.2M
Series B
$8.3M
Series C
$19.1M
Angel/Seed (1996): $2.5M with participation from Medtronic, Inc. and Advanced Technology Ventures
Series A (1997): $3.2M, investors not publicly disclosed
Series B (1998): $8.3M, investors not publicly disclosed
Series C (2000): $19.1M, investors not publicly disclosed
Key Investors in Cepheid
Medtronic, Inc.
Medtronic is a global healthcare technology company founded in 1949 that develops and manufactures medical devices, therapies, and digital health solutions. Its portfolio spans cardiovascular, neuroscience, medical surgical, and diabetes technologies.
Advanced Technology Ventures
Founded in 1979, Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm with $1.4 billion in capital under management, focusing on communications, healthcare, and IT infrastructure.
What's next for Cepheid?
Looking ahead, the infusion of capital will likely be directed toward expanding the company's diagnostic test menu and scaling its manufacturing capabilities to meet global demand. As the healthcare landscape shifts toward personalized medicine and rapid diagnostics, Cepheid is strategically aligned to capitalize on these trends. The firm's focus will remain on enhancing the throughput and sensitivity of its systems, potentially exploring new therapeutic areas for genetic screening. By leveraging its established market presence and the support of its strategic partners, Cepheid is poised to maintain its competitive advantage in the molecular diagnostics space, driving innovation that improves patient outcomes and operational efficiency for clinical providers worldwide.
See full Cepheid company page
